RV-1770
Respiratory Syncytial Virus (RSV) Prophylaxis
Phase 1Active
Key Facts
About RNAimmune
RNAimmune is an emerging biotech player in the mRNA space, spun out from Sirnaomics in 2020. The company is advancing a pipeline of mRNA-based prophylactic vaccines and cancer immunotherapies, with its lead RSV vaccine candidate having entered Phase 1 clinical trials in the US. Backed by a $27 million Series A round, RNAimmune is building on a foundation of over 20 years of mRNA expertise and has established key partnerships and licensing deals, particularly in China, to advance its programs.
View full company profile